Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: Posttreatment 1-year results of three Turkish centres

Basit Öğe Kaydı
dc.contributor.authorYamazhan T.
dc.contributor.authorKurtaran B.
dc.contributor.authorPullukçu H.
dc.contributor.authorYüksel E.
dc.contributor.authorÖzkaya D.
dc.contributor.authorTaşbakan M.I.
dc.contributor.authorSipahi O.R.
dc.contributor.authorDurusoy R.
dc.contributor.authorSalih Zeki Aksu H.
dc.date.accessioned2019-10-27T08:22:42Z
dc.date.available2019-10-27T08:22:42Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractIn this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2.9% and 60.2%, whereas 1-year sustained virological response rates were 0 and 33.3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P50.028; Mann–Whitney U test, P50.023). Overall non-response rates to PEGIFN were high (57.1%). Results in HBeAg-positive cases were disappointing. © 2014 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia.en_US
dc.identifier.doi10.1179/1973947813Y.0000000152en_US
dc.identifier.endpage341en_US
dc.identifier.issn1120-009X
dc.identifier.issue6en_US
dc.identifier.pmid24171823en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage339en_US
dc.identifier.urihttps://doi.org/10.1179/1973947813Y.0000000152
dc.identifier.urihttps://hdl.handle.net/11454/26300
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherManey Publishingen_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectGenotypeen_US
dc.subjectPegylated interferonsen_US
dc.subjectPrimary non-respondersen_US
dc.subjectSecondary non-respondersen_US
dc.subjectTreatment responseen_US
dc.titlePegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: Posttreatment 1-year results of three Turkish centresen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu